SILVER SPRING, Md., Oct. 28, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2014.
“We are pleased with our overall core operating results for the third quarter,” said Martine Rothblatt, Ph.D., United Therapeutics’ Chairman and Chief Executive Officer. “We are also happy with the progress of the Orenitram launch, and look forward to building on the momentum we have established.”
Total revenues for the quarter ended September 30, 2014 were $330.0 million, up from $302.2 million for the quarter ended September 30, 2013. Net loss for the quarter ended September 30, 2014 was $25.2 million or $0.53 per basic share, compared to net income of $62.7 million or $1.25 per basic share for the same quarter in 2013. Gross margin from sales was $287.5 million for the quarter ended September 30, 2014, compared to $269.3 million for the same quarter last year. Non-GAAP earnings(1) for the quarter ended September 30, 2014 were $207.9 million, compared to $149.3 million for the same quarter in 2013.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
